MTNB
Matinas BioPharma Holdings, Inc.
$0.36
+0.02 (+4.69%)
At close · Jul 16
Going-concern doubt
— flagged May 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company does not believe that the cash and cash equivalents on hand are sufficient to fund planned operations for a period of at least twelve months from the filing date of these financial statements. As a result, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed May 8, 2026
Market Cap
$2.28M
Shares
6,406,191
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.36
Open$0.34
Day$0.32–0.38
52W$0.31–3.09
Avg vol 30d759K
Short int6K · 0.1% float · 1.0d
Short vol60%
Last earningsAug 14, 2024
DataJan 2020–Jul 2026
Filing10-Q · May 8
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−56%
below
Price vs 50-day avg
−46%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−50%
trailing
6-month return
−39%
trailing
YTD return
−39%
this year
Relative strength
−48%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 28 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.10% of float · ▼ -70.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — mid 1-yr range
Squeeze score
28
low risk · 0–100
Fundamentals
Revenue growth
−20%
Y/Y
EPS growth
+60%
Y/Y
Free cash flow
$-7.2M
Balance sheet
$4.0M
net cash
Quant / Vol
risk profile
Volatility
127%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
26.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−56%
Bearish
Price vs 50-day avg
−46%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
1 of 28 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.10% of float · ▼ -70.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
28 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 2%
52-wk high $3
vs 200-day avg -56%
vs 50-day avg -46%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MTNB
this stock
Matinas BioPharma Holdings, Inc.
|
$2.28M | -39.1% | -20.0% | — | 0.1% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +4.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +7.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -11.9% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MTNB | -43.1% | -50.4% | -39.5% | -41.7% | -39.1% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -42.9% | -50.5% | -48.5% | -42.2% | -49.2% |